<p>Prognostic analysis of patients with mutant and wild-type <em>EGFR</em> gene lung adenocarcinoma</p>

Abstract

Purpose The purpose of this study was to investigate the relationship between epidermal growth factor receptor ( EGFR ) gene mutation and clinicopathological features of lung adenocarcinoma, and the prognostic and therapeutic value of EGFR . Methods EGFR gene mutations were detected in 424 patients with lung adenocarcinoma by amplification refractory mutation system (ARMS). Results The total EGFR gene mutation rate was 55.2% (234/424) and EGFR gene mutation rates were statistically different in gender, smoking status, and pathological degree ( P <0.05). The overall survival (OS) time of lung adenocarcinoma patients with mutation of exon 18 was lower than those with mutation of exon 19 and exon 21 (both P <0.05), but no significant difference was seen between those with mutation of exon 19 and exon 21 ( P >0.05). Among 424 cases of lung adenocarcinoma, multivariate analysis showed that EGFR gene mutation, age, gender, clinical stages, and pathological degree ( P <0.05) were statistically significant prognostic factors. In multivariate analysis, prognostic factors of patients with EGFR gene mutation were associated with EGFR-TKI treatment, surgery treatment, pathological degree, clinical stages, and age ( P <0.05), whereas in patients without EGFR gene mutation, prognostic factors were related to surgery treatment, pathological degree, clinical stages, gender, age, and smoking status ( P <0.05). Conclusion The OS time of patients with mutation of exon 18 was lower than those of exon 19 and exon 21. EGFR-TKI treatment was an independent positive predictor in patients with EGFR gene mutation. Surgery treatment, age, clinical stages, and pathological degree were independent prognostic factors in Chinese patients with lung adenocarcinoma no matter whether with EGFR gene mutation or not.

The Diagnostic Accuracy of Liquid Biopsy in EGFR-Mutated NSCLC: A Systematic Review and Meta-Analysis of 40 Studies

“…Moreover, our results also demonstrated that EGFR mutation was combined with better treatment response and PFS, which might be associated with the therapeutic efficacy of second-generation or third-generation EGFR-TKI. 66 In contrast, patients without EGFR mutation may not benefit from EGFR-TKI, thus resulting in a higher rate of SD and PD. There was no significant difference in OS, however, which may be affected by the short follow-up period in some studies.…”

3D radiomics predicts EGFR mutation, exon-19 deletion and exon-21 L858R mutation in lung adenocarcinoma

“…Patients who have tumors harboring one of these two mutations exhibit a greater objective response rate to afatinib, erlotinib, and gefitinib (10). There is differential prognosis based on EGFR mutation: the overall survival time for patients with exon-19 and -21 mutations with targeted therapy was found to be 41 to 44 months, longer than those with exon-18 mutation (19 months) (11). Therefore, detection of specific EGFR mutations may be of interest in guiding the application of targeted therapy in lung adenocarcinoma patients.…”

<p>Concurrent proton-pump inhibitors increase risk of death for lung cancer patients receiving 1st-line gefitinib treatment - a nationwide population-based study</p>

“…Over the last decade, one of the most important advances for the therapy of non-small cell lung cancer (NSCLC) was the development of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) 2,3. EGFR mutations are detected in more than 50% of patients with the histological subtype of adenocarcinoma in East Asia 4,5. Among patients harboring an activating EGFR mutation, EGFR-TKIs significantly improve not only the patient’s quality of life,6 but also progression-free survival (PFS)7–9 and overall survival (OS)10 compared with platinum-based doublet chemotherapy.…”